Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aralez Pharmaceuticals Inc.ARLZ · Entity 165961 | Director | May 11, 2017 | May 13, 2017 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2026 | May 04, 2026 |
| Liquidia CorpLQDA · Entity 1860 | Director · Chief Executive Officer | November 19, 2020 | November 20, 2020 |
| Liquidia Technologies IncLQDA · Entity 145051 | Director · Chief Executive Officer | March 18, 2020 | March 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aralez Pharmaceuticals Inc.
Report date May 11, 2017 · Filed May 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 73,869 |
Reported balance
After 2017-05-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-05-11 · Grant · Acquired 7,500 · Balance 73,869 F1: Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date. Vested shares will be delivered to the Reporting Person on the earlier of the date that the Reporting Person ceases to provide services to the Board and the date of a Change of Control, as defined in the Issuer's 2016 Amended and Restated Long-Term Incentive Plan, in either case provided that the Restricted Stock Units are vested on such date. F2: Includes 66,369 shares of Common Stock and 7,500 Restricted Stock Units. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2027-05-11 | Direct | 15,000 |
Reported balance
After 2017-05-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-05-11 · Grant · Acquired 15,000 · Balance 15,000 F3: The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date. Vested shares will be delivered to the Reporting Person on the earlier of the date that the Reporting Person ceases to provide services to the Board and the date of a Change of Control, as defined in the Issuer's 2016 Amended and Restated Long-Term Incentive Plan, in either case provided that the Restricted Stock Units are vested on such date.
F2: Includes 66,369 shares of Common Stock and 7,500 Restricted Stock Units.
F3: The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date.
Emergent BioSolutions Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,847 |
Reported balance
After 2026-04-30 transaction · row 1
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 25,344 · Balance 160,847 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2033-04-30 | Direct | 11,296 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 11,296 · Balance 11,296 F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Liquidia Corp
Report date November 19, 2020 · Filed November 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,512 |
Ending reported balance
After 2020-11-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-11-19 · Exercise / conversion · Acquired 62,885 · Balance 114,196 Row 2 · 2020-11-19 · Tax withholding · Disposed 35,684 · Balance 78,512 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2020-11-23 | Direct | 0 |
Reported balance
After 2020-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-19 · Exercise / conversion · Disposed 62,885 · Balance 0 F1: 25% of the shares underlying the option vested on May 12, 2011, and 2.084% of the shares underlying the option vested monthly thereafter, becoming fully vested on November 23, 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option vested on May 12, 2011, and 2.084% of the shares underlying the option vested monthly thereafter, becoming fully vested on November 23, 2014.
Liquidia Technologies Inc
Report date March 18, 2020 · Filed March 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,627 |
Reported balance
After 2020-03-18 transaction · row 1
1 source rowRow 1 · 2020-03-18 · Grant · Acquired 30,400 · Balance 86,627 F1: The restricted stock units (RSUs) vest and settle into common stock over a four-year period with 25% of the RSUs vesting and settling into common stock on the one year anniversary of the grant date and the remaining 75% of the RSUs vesting and settling into common stock in equal quarterly installments over the next three years, becoming fully vested on March 18, 2024. |
| Employee Stock Option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $3.31 · Expires 2030-03-18 | Direct | 121,600 |
Reported balance
After 2020-03-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-18 · Grant · Acquired 121,600 · Balance 121,600 F2: The option vests in equal monthly installments over a four-year period, becoming fully vested on March 18, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (RSUs) vest and settle into common stock over a four-year period with 25% of the RSUs vesting and settling into common stock on the one year anniversary of the grant date and the remaining 75% of the RSUs vesting and settling into common stock in equal quarterly installments over the next three years, becoming fully vested on March 18, 2024.
F2: The option vests in equal monthly installments over a four-year period, becoming fully vested on March 18, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2026 Filed May 4, 2026 21:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 11,296 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001493692-26-000003 · wk-form4_1777930061.xml · derivative · entry 2 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,296 Underlying: Common Stock · 11,296 shares Expires 2033-04-30 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2026 Filed May 4, 2026 21:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 25,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001493692-26-000003 · wk-form4_1777930061.xml · nonDerivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,847 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 15,824 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001367644-25-000109 · wk-form4_1746232276.xml · derivative · entry 2 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,572 Underlying: Common Stock · 15,824 shares Expires 2032-04-29 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 34,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000109 · wk-form4_1746232276.xml · nonDerivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,503 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| March 12, 2025 Filed Mar 12, 2025 22:13 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 35,000 | $5.83 | $204,050.00 |
DisclosureSEC source: 0001367644-25-000060 · wk-form4_1741817592.xml · nonDerivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,100 F1 · price: On March 12, 2025, Mr. Fowler sold an aggregate of 35,000 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, the sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $5.81 to $5.89. The Company maintains a record of the transactions and copies will be provided upon request. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 25,748 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001367644-24-000088 · wk-form4_1716946866.xml · derivative · entry 2 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,748 Underlying: Common Stock · 25,748 shares Expires 2031-05-22 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 17,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-24-000088 · wk-form4_1716946866.xml · nonDerivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,100 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 23:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 118,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000179 · wk-form4_1696547413.xml · nonDerivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,670 F1 · shares: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. These restricted stock units will vest in three equal installments over a three-year period assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 23:45 UTC | Liquidia Corp LQDA · Entity 1860 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 62,885 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001104659-20-128078 · a4.xml · derivative · entry 3 Fowler Neal Franklin · CIK 0001493692 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,885 shares Expires 2020-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying the option vested on May 12, 2011, and 2.084% of the shares underlying the option vested monthly thereafter, becoming fully vested on November 23, 2014. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 23:45 UTC | Liquidia Corp LQDA · Entity 1860 | Tax withholdingCommon Stock | 35,684 | $3.40 | $121,325.60 |
DisclosureSEC source: 0001104659-20-128078 · a4.xml · nonDerivative · entry 2 Fowler Neal Franklin · CIK 0001493692 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,512 Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 23:45 UTC | Liquidia Corp LQDA · Entity 1860 | Exercise / conversionCommon Stock | 62,885 | $1.85 | $116,337.25 |
DisclosureSEC source: 0001104659-20-128078 · a4.xml · nonDerivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 23:08 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantEmployee Stock Option (right to buy · Derivative | 121,600 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001104659-20-036983 · a4.xml · derivative · entry 2 Fowler Neal Franklin · CIK 0001493692 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,600 Underlying: Common Stock · 121,600 shares Expires 2030-03-18 F2 · derivative.exercise_date: The option vests in equal monthly installments over a four-year period, becoming fully vested on March 18, 2024. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 23:08 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantCommon Stock | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-036983 · a4.xml · nonDerivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,627 F1 · shares: The restricted stock units (RSUs) vest and settle into common stock over a four-year period with 25% of the RSUs vesting and settling into common stock on the one year anniversary of the grant date and the remaining 75% of the RSUs vesting and settling into common stock in equal quarterly installments over the next three years, becoming fully vested on March 18, 2024. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 22:11 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantEmployee Stock Option (right to buy) · Derivative | 96,500 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0001104659-19-006376 · a4.xml · derivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,500 Underlying: Common Stock · 96,500 shares Expires 2029-02-05 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on February 5, 2023. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 20:06 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantCommon Stock | 11,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-062291 · a4.xml · nonDerivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,227 F1 · balance_after: Includes (i) 44,989 shares of common stock and (ii) 11,238 restricted stock units ("RSUs") granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Fowler's continuous service as of each such date. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 21:02 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantStock Option · Derivative | 192,008 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047751 · a4.xml · derivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,008 Underlying: Common Stock · 192,008 shares Expires 2028-07-25 F1 · derivative.exercise_date: 25% of such options vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments after July 25, 2019, subject to Mr. Fowler's continuous service as of each such date. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:50 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-17-032407 · a4.xml · derivative · entry 2 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares, without par value · 15,000 shares Expires 2027-05-11 F3 · derivative.exercise_date: The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:50 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantCommon Shares, without par value | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-032407 · a4.xml · nonDerivative · entry 1 Fowler Neal Franklin · CIK 0001493692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,869 F1 · kind: Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date. Vested shares will be delivered to the Reporting Person on the earlier of the date that the Reporting Person ceases to provide services to the Board and the date of a Change of Control, as defined in the Issuer's 2016 Amended and Restated Long-Term Incentive Plan, in either case provided that the Restricted Stock Units are vested on such date. F2 · balance_after: Includes 66,369 shares of Common Stock and 7,500 Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.